Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation
- Creator: Zhu, Chao , Kalincik, Tomas , Patti, Francesco , Grand'Maison, Francois , Hodgkinson, Suzanne , Grammond, Pierre , Lechner-Scott, Jeannette , Butler, Ernest , Prat, Alexandre , Girard, Marc , Duquette, Pierre , Macdonell, Richard A. L. , Horakova, Dana , Weinstock-Guttman, B , Ozakbas, S , Slee, M , Sa, MJ , Van Pesch, V , Barnett, M , Van Wijmeersch, B , Gerlach, O , Prevost, J , Terzi, M , Zhou, Zhen , Boz, C , Laureys, G , Van Hijfte, L , Kermode, AG , Garber, J , Yamout, B , Khoury, SJ , Merlo, D , Monif, M , Jokubaitis, V , Buzzard, Katherine , van der Walt, A , Butzkueven, H , MSBase, SG , Skibina, Olga , Alroughani, Raed , Izquierdo, Guillermo , Eichau, Sara , Kuhle, Jens
- Resource Type: journal article
- Date: 2023
Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis
- Creator: Zhu, Chao , Zhou, Zhen , Roos, Izanne , Merlo, Daniel , Kalincik, Tomas , Ozakbas, Serkan , Skibina, Olga , Kuhle, Jens , Hodgkinson, Suzanne , Boz, Cavit , Alroughani, Raed , Lechner-Scott, Jeannette , Barnett, Michael , Izquierdo, Guillermo , Prat, Alexandre , Horakova, Dana , Havrdova, Eva Kubala , Macdonell, Richard , Patti, Francesco , Khoury, Samia Joseph
- Resource Type: journal article
- Date: 2022